✦ LIBER ✦

Benefit–Risk Assessment of Rosuvastatin in the Treatment of Atherosclerosis and Related Diseases

✍ Scribed by Kostapanos, Michael S.; Rizos, Christos V.; Elisaf, Moses S.

Book ID: 125386829
Publisher: Springer International Publishing AG
Year: 2014
Tongue: English
Weight: 474 KB
Volume: 37
Category: Article
ISSN: 0114-5916
DOI: 10.1007/s40264-014-0169-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Risk and Benefit Assessment of Treatme

A Risk and Benefit Assessment of Treatment for AIDS-Related Kaposi’s Sarcoma

✍ Guglielmo Nasti, Domenico Errante, Sandra Santarossa, Emmanuela Vaccher, Dr Umbe 📂 Article 📅 1999 🏛 Springer International Publishing AG 🌐 English ⚖ 288 KB

Benefit-Risk Assessment of Zaleplon in t

Benefit-Risk Assessment of Zaleplon in the Treatment of Insomnia

✍ Dr Joseph Barbera, Colin Shapiro 📂 Article 📅 2005 🏛 Springer International Publishing AG 🌐 English ⚖ 139 KB

Benefit-Risk Assessment of Rofecoxib in

Benefit-Risk Assessment of Rofecoxib in the Treatment of Osteoarthritis

✍ Helmut Schmidt, Barry G. Woodcock, Professor Dr Gerd Geisslinger 📂 Article 📅 2004 🏛 Springer International Publishing AG 🌐 English ⚖ 137 KB

Predicting risk and treatment benefit in

Predicting risk and treatment benefit in atherosclerosis: the role of C-reactive protein

✍ Wolfgang Koenig 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 152 KB

Benefit-Risk Assessment of Dronedarone i

Benefit-Risk Assessment of Dronedarone in the Treatment of Atrial Fibrillation

✍ Ahmed M. A. Adlan, Gregory Y. H. Lip 📂 Article 📅 2013 🏛 Springer International Publishing AG 🌐 English ⚖ 439 KB

Benefit-Risk Assessment of Bevacizumab i

Benefit-Risk Assessment of Bevacizumab in the Treatment of Breast Cancer

✍ Rodrigo Dienstmann, Felipe Ades, Kamal S. Saini, Otto Metzger-Filho 📂 Article 📅 2012 🏛 Springer International Publishing AG 🌐 English ⚖ 143 KB